Claims for Patent: 6,265,632

Summary for Patent: 6,265,632

Title:	Animal model for fibroblast growth factor receptor associated chondrodysplasia
Abstract:	A genetically modified animal is disclosed. The animal has a genetically modified fibroblast growth factor receptor gene integrated in at least one locus in its genome. The genetically modified fibroblast growth factor receptor gene encodes a modified fibroblast growth factor receptor protein, that, when expressed, results in an integral membrane protein having a gain of function.
Inventor(s):	Yayon; Avner (Moshav Sitria, IL), Segev; Orit (Rehovot, IL)
Assignee:	Yeda Research and Development Co. Ltd. (Rehovot, IL) Prochon Biotech Ltd. (Rehovot, IL)
Application Number:	09/383,630
Patent Claims:	1. A transgenic mouse whose genome comprises a nucleic acid construct, wherein the construct comprises a DNA segment consisting of nt 264-2719 of the sequence disclosed in SEQ ID NO 2 and said DNA segment comprises the promoter region and 1st exon of the mouse fibroblast growth factor receptor 3 (FGFR3) gene operatively linked to a DNA fragment encoding a mutant of the c form of human FGFR3 wherein the Glycine residue at position 380 is substituted with Arginine, and wherein said transgenic mouse exhibits the characteristics of human achondroplasia that include, shortening of the limbs, midface hypoplasia, and large skull. 2. The transgenic mouse of claim 1, wherein the transgene is in a hetero- or homo-zygous form. 3. The transgenic mouse of claim 1, wherein the transgenic mouse is a model for human achondroplasia. 4. The transgenic mouse of claim 1, wherein both alleles of the endogenous FGFR3 gene of the transgenic mouse have been inactivated such that said endogenous FGFR3 gene does not produce FGFR3 protein. 5. The transgenic mouse of claim 1, wherein the mouse produces endogenous active FGFR3 protein. 6. A transgenic mouse whose genome comprises a nucleic acid construct, wherein the construct comprises a DNA segment consisting of nt 264-5255 of the sequence disclosed in SEQ ID NO 2 and said DNA segment comprises the promoter region, first exon, first intron, second exon, and 1.66 kb 5' sequences of the mouse FGFR3 gene operatively linked to a DNA fragment encoding a mutant of the murine FGFR3 wherein the Glycine residue at position 374 is substituted with Arginine, and wherein said transgenic mouse exhibits the characteristics of human achondroplasia that include, shortening of the limbs, midface hypoplasia, and large skull. 7. The transgenic mouse of claim 6, wherein the transgene is in a hetero- or homozygous form. 8. The transgenic mouse of claim 6, wherein the transgenic mouse is a model for human achondroplasia. 9. The transgenic mouse of claim 6, wherein the mouse produces endogenous active FGFR3 protein.

Details for Patent 6,265,632

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-08-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-08-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-08-27